πŸ‡ΊπŸ‡Έ FDA
Patent

US 11478542

Immunogenic RSV polypeptides

granted A61KA61K2039/523A61K2039/54

Quick answer

US patent 11478542 (Immunogenic RSV polypeptides) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K2039/523, A61K2039/54, A61K2039/55, A61K2039/555